Hertfordshire and West Essex ICB
Prescribing, Policies and Pathways
Prescribing, Policies and Pathways
The last day of operation for Hertfordshire and West Essex ICB was 31 March 2026. The information on this website has not been updated since 31 March 2026. The legacy policies, prescribing recommendations and pathways can be accessed on this website. Find out more
or
| Medicine / Guideline | Indication | RAG rating | Document type | Place |
|---|---|---|---|---|
| Acetylcholinesterase (AChE) inhibitor | Alzheimer's disease dementia | Amber protocol | Shared care protocol | West Essex |
| Acetylcholinesterase (AChE) inhibitor | Alzheimer's disease dementia | Amber initiation | Prescribing support document | East and North Hertfordshire, South and West Hertfordshire |
| Acute trial of rimegepant for treatment of migraine - patient questionnaire | Migraine - treating | Green | Primary Care prescribing resource | Hertfordshire and West Essex ICB |
| Alemtuzumab | Highly active relapsing remitting multiple sclerosis (NHSE) | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Amantadine | Parkinson's disease | Amber initiation | n/a | Hertfordshire and West Essex ICB |
| Amifampridine | Lambert-Eaton myasthenic syndrome (NHSE) | Double Red | Prescribing guideline | Hertfordshire and West Essex ICB |
| Anti-platelet Therapy in Suspected TIA | n/a | Clinical pathways | Hertfordshire and West Essex ICB | |
| Anticholinergic burden (ACB) | Structured medication review Eclipse Live | n/a | Primary Care prescribing resource | Hertfordshire and West Essex ICB |
| Anticholinergic burden (ACB) | Structured medication review Hints and tips | n/a | Primary Care prescribing resource | Hertfordshire and West Essex ICB |
| Apomorphine | Parkinson's disease | Red | Decision document | Hertfordshire and West Essex ICB |
| Aripiprazole oral solution SF to orodispersible tablets Patient letter | Licensed Indications | n/a | Primary Care prescribing resource | Hertfordshire and West Essex ICB |
| Atogepant | Migraine - chronic | Amber initiation | Prescribing pathway | Hertfordshire and West Essex ICB |
| Atogepant | Migraine - episodic | Amber initiation | Prescribing pathway | Hertfordshire and West Essex ICB |
| Atogepant | Migraine-prevention | Amber initiation | Prescribing support document | Hertfordshire and West Essex ICB |
| Atomoxetine | Attention deficit hyperactivity disorder (ADHD) | Amber protocol | Shared care protocol | East and North Hertfordshire, South and West Hertfordshire |
| Atomoxetine | Attention deficit hyperactivity disorder (ADHD) | Amber protocol | Shared care protocol | West Essex |
| Attention deficit hyperactivity disorder (ADHD) | ADHD shared care protocol | Amber protocol | Shared care protocol | West Essex |
| Attention deficit hyperactivity disorder (ADHD) | ADHD shared care protocol - children, young people and adults | Amber protocol | Shared care protocol | East and North Hertfordshire, South and West Hertfordshire |
| Baclofen - oral | Spasticity generalised in adults with cerebral palsy | Green | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Baclofen oral | Spasticity generalised in paediatrics with cerebral palsy | Green | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Bobath Therapy | n/a | Clinical policy | Hertfordshire and West Essex ICB | |
| Botulinum toxin type A | Focal spasticity, Hemi-facial spasm, Blepharospasm, Cervical dystonia, Frey’s syndrome, Chronic anal fissure, Dysphagia, Hirschsprung’s disease, Overactive bladder,Masseteric hypertrophy and temporomandibular disorders | Red | Prescribing guideline | Hertfordshire and West Essex ICB |
| Brain MRI for the exclusion of Brain and CNS Cancer | n/a | n/a | South and West Hertfordshire | |
| Brivaracetam | Epilepsy | Amber initiation | Decision document | Hertfordshire and West Essex ICB |
| Cannabidiol (Epidiyolex®) | Tertiary care indication (NHSE) Suitable for shared care between tertiary and secondary care providers. Adjunctive treatment with clobazam for treating seizures associated with Dravet syndrome and Lennox-Gastaut syndrome (LGS) | Red | Decision document | Hertfordshire and West Essex ICB |
| Cannabis-based medicinal preparations | Intractable nausea & vomiting, chronic pain, spasticity and severe treatment-resistant epilepsy | Red | Position statement | Hertfordshire and West Essex ICB |
| Carbamazepine | Epilepsy | Green | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Cenobamate | Epilepsy | Amber initiation | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Cladribine | Relapsing–remitting multiple sclerosis (NHSE) | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Clomipramine | Narcolepsy (tertiary centre only) some have agreed amber protocol | Amber initiation | n/a | Hertfordshire and West Essex ICB |
| Clonazepam | Epilepsy | Amber initiation | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Co-beneldopa | Parkinson's disease | Amber initiation | n/a | Hertfordshire and West Essex ICB |
| Co-careldopa | Parkinson's disease | Amber initiation | n/a | Hertfordshire and West Essex ICB |
| Co-careldopa (Carbidopa/levodopa) intestinal gel | Parkinson's disease (NHSE) | Red | Decision document | Hertfordshire and West Essex ICB |
| Co-careldopa Intestinal Gel (Duodopa) | Parkinson's Disease (NHSE tertiary centre only) | Red | n/a | Hertfordshire and West Essex ICB |
| Co-proxamol | Pain | Double Red | Prescribing guideline | Hertfordshire and West Essex ICB |
| Co-proxamol | Pain | n/a | Patient information | Hertfordshire and West Essex ICB |
| Cytisine (cytisinicline) | Smoking cessation | Red | n/a | Hertfordshire and West Essex ICB |
| Daridorexant | Long-term insomnia | Green | Prescribing support document | Hertfordshire and West Essex ICB |
| Daridorexant | Insomnia | Green | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Daridorexant | Long-term insomnia | Green | Patient information | Hertfordshire and West Essex ICB |
| Delta-9-tetrahydrocannabinol [THC] and cannabidiol [CBD] spray (Sativex®) | Spasticity in multiple sclerosis (MS) | Red | Decision document | Hertfordshire and West Essex ICB |
| Dependence forming medicine | Pain - ECF FAQs | n/a | Primary Care prescribing resource | Hertfordshire and West Essex ICB |
| Dexamfetamine | Attention deficit hyperactivity disorder (ADHD) | Amber protocol | Shared care protocol | East and North Hertfordshire, South and West Hertfordshire |
| Dexamfetamine | Attention deficit hyperactivity disorder (ADHD) | Amber protocol | Shared care protocol | West Essex |
| Dexamfetamine | Narcolepsy (tertiary centre only) some have agreed amber protocol | Amber initiation | n/a | Hertfordshire and West Essex ICB |
| Domperidone | Nausea vomiting in children | Double Red | Prescribing guideline | Hertfordshire and West Essex ICB |
| Donepezil | Alzheimer's disease dementia | Amber initiation | Prescribing support document | East and North Hertfordshire, South and West Hertfordshire |
| Donepezil | Alzheimer's disease dementia | Amber protocol | Shared care protocol | West Essex |
| Donepezil Orodispersible tablets to tablets Patient letter | Licensed Indications | n/a | Primary Care prescribing resource | Hertfordshire and West Essex ICB |
| Dosulepin stopping and switching guidance | Depression | Double Red | Prescribing guideline | Hertfordshire and West Essex ICB |
| Drug Titration and Review for Neuropathic Pain | n/a | Clinical pathways | Hertfordshire and West Essex ICB | |
| Electronic Cigarettes and other novel nicotine containing products | Tobacco dependance | Red | Position statement | Hertfordshire and West Essex ICB |
| Entacapone | Parkinson's disease | Amber initiation | n/a | Hertfordshire and West Essex ICB |
| Epilepsy, Fits and Seizures | n/a | Clinical pathways | Hertfordshire and West Essex ICB | |
| Eptinezumab | Migraine - episodic | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
| Eptinezumab | Migraine - chronic | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
| Erenumab | Migraine - chronic | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
| Erenumab | Migraine - episodic | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
| Ethosuximide | Absence seizures, atypical absence seizures (adjunct) and myoclonic seizures in adults and children. | Amber initiation | Prescribing support document | Hertfordshire and West Essex ICB |
| Ethosuximide capsules | Absence seizures, atypical absence seizures (adjunct) and myoclonic seizures in adults and children. | Amber initiation | Primary Care prescribing resource | Hertfordshire and West Essex ICB |
| Ethosuximide syrup | Absence seizures, atypical absence seizures (adjunct) and myoclonic seizures in adults and children. | Amber initiation | Primary Care prescribing resource | Hertfordshire and West Essex ICB |
| Fampridine | Multiple sclerosis (NHSE) | Double Red | Decision document | Hertfordshire and West Essex ICB |
| Fentanyl immediate release (IR) | Pain (except for palliative care) | Double Red | Prescribing guideline | Hertfordshire and West Essex ICB |
| Fentanyl Immediate-Release Patient Information Leaflet | Pain (except for palliative care) | n/a | Patient information | Hertfordshire and West Essex ICB |
| Fingolimod | Highly active relapsing–remitting multiple sclerosis (NHSE) | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Fluoxetine oral solution to dispersible tablets switch Patient letter | Licensed Indications | n/a | Primary Care prescribing resource | Hertfordshire and West Essex ICB |
| Fremanezumab | Migraine - chronic | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
| Fremanezumab | Migraine - episodic | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
| Functional Electrical Stimulation Prior Approval Form | Red | Prior approval form | Hertfordshire and West Essex ICB | |
| Gabapentin | Epilepsy | Amber initiation | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Galantamine | Alzheimer's disease dementia | Amber initiation | Decision document | East and North Hertfordshire, South and West Hertfordshire |
| Galantamine | Alzheimer's disease dementia | Amber protocol | Shared care protocol | West Essex |
| Galcanezumab | Migraine - chronic | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
| Galcanezumab | Migraine - episodic | Red | Prescribing pathway | Hertfordshire and West Essex ICB, East and North Hertfordshire, South and West Hertfordshire, West Essex |
| Glatiramer | Multiple sclerosis (NHSE) | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Glycopyrronium bromide oral | Hypersalivation - adults | Double Red | n/a | Hertfordshire and West Essex ICB |
| Guanfacine | Atttention deficit hyperactivity disorder (ADHD) - in children | Amber protocol | Shared care protocol | East and North Hertfordshire, South and West Hertfordshire |
| Guanfacine | Atttention deficit hyperactivity disorder (ADHD) - in children | Amber protocol | Shared care protocol | West Essex |
| Headache | n/a | Clinical pathways | Hertfordshire and West Essex ICB, South and West Hertfordshire | |
| Lacosamide | Epilepsy | Amber initiation | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Lamotrigine | Epilepsy | Amber initiation | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Levetiracetam | Epilepsy | Amber initiation | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Lidocaine plaster patient information Leaflet | Pain | n/a | Patient information | Hertfordshire and West Essex ICB |
| Lidocaine Plasters | All except post herpetic neuralgia and non post herpetic neuralgia localised neuropathy | Double Red | n/a | Hertfordshire and West Essex ICB |
| Lidocaine plasters deprescribing guide | Neuropathic pain | n/a | Prescribing guideline | Hertfordshire and West Essex ICB |
| Lisdexamfetamine | Attention deficit hyperactivity disorder (ADHD) | Amber protocol | Shared care protocol | East and North Hertfordshire, South and West Hertfordshire |
| Lisdexamfetamine | Attention deficit hyperactivity disorder (ADHD) | Amber protocol | Shared care protocol | West Essex |
| Long term insomnia management including Cognitive Behavioural Therapy for insomnia (CBT-I) Frequently Asked Questions (FAQs) for adult patients | Long-term insomnia | n/a | Patient information | Hertfordshire and West Essex ICB |
| Mechanical Insufflation-Exsufflation (MI-E) Devices / CoughAssist | n/a | Clinical policy | Hertfordshire and West Essex ICB | |
| Medication Overuse Headache | n/a | Decision document | South and West Hertfordshire | |
| Melatonin | Insomnia adults excluding learning disabilities | Double Red | n/a | Hertfordshire and West Essex ICB |
| Melatonin | Insomnia - Neurodevelopmental Disorders in patients under the age of 18 years | Amber initiation | Prescribing support document | Hertfordshire and West Essex ICB |
| Melatonin | Insomnia - Learning disability in adults and paediatrics | Amber initiation | Prescribing support document | Hertfordshire and West Essex ICB |
| Melatonin | Insomnia - product options in neurodevelopmental disorders in patients aged 2 to under 18 years | Amber initiation | Prescribing guideline | Hertfordshire and West Essex ICB |
| Melatonin | Insomnia - product options in adult and paediatric patients with learning disabilities | Amber initiation | Prescribing guideline | Hertfordshire and West Essex ICB |
| Melatonin (Slenyto) | Insomnia | Double Red | Decision document | Hertfordshire and West Essex ICB |
| Memantine | Alzheimer's disease dementia | Amber initiation | Prescribing support document | East and North Hertfordshire, South and West Hertfordshire |
| Memantine | Alzheimer's disease dementia | Amber protocol | Shared care protocol | West Essex |
| Methylphenidate | Attention deficit hyperactivity disorder (ADHD) | Amber protocol | Shared care protocol | East and North Hertfordshire, South and West Hertfordshire |
| Methylphenidate | Attention deficit hyperactivity disorder (ADHD) | Amber protocol | Shared care protocol | West Essex |
| Methylphenidate | Narcolepsy (tertiary centre only) some have agreed amber protocol | Amber initiation | n/a | Hertfordshire and West Essex ICB |
| Mexiletine | Myotonia in non-dystrophic myotonic disorders (NHSE) | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Midazolam (Buccolam) | Epilepsy (prescribe by brand) | Amber initiation | Prescribing guideline | Hertfordshire and West Essex ICB |
| Midazolam (Epistatus) | Epilepsy (prescribe by brand) | Amber initiation | Prescribing guideline | Hertfordshire and West Essex ICB |
| Migraine | Migraine - chronic | n/a | Prescribing pathway | Hertfordshire and West Essex ICB |
| Migraine | Migraine - episodic | n/a | Prescribing pathway | Hertfordshire and West Essex ICB |
| Migraine in Adults | n/a | Clinical pathways | Hertfordshire and West Essex ICB | |
| Migraine treatment in adults | Migraine | n/a | Prescribing guideline | Hertfordshire and West Essex ICB |
| Migraine treatment in adults | Migraine | n/a | Patient information | Hertfordshire and West Essex ICB |
| Modafinil | Narcolepsy (tertiary centre only) some have agreed amber protocol | Amber initiation | n/a | Hertfordshire and West Essex ICB |
| Motor Neurone Disease (MND) | n/a | Clinical pathways | Hertfordshire and West Essex ICB | |
| Multiple Sclerosis (MS) | n/a | Clinical pathways | Hertfordshire and West Essex ICB | |
| Nabilone | Intractable chemotherapy induced nausea and vomiting | Red | Decision document | Hertfordshire and West Essex ICB |
| Natalizumab | Multiple sclerosis (NHSE) | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Neuropathic pain | Neuropathic pain | n/a | Prescribing guideline | Hertfordshire and West Essex ICB |
| Neuropathic Pain Drug Titration and Review | n/a | Clinical pathways | East and North Hertfordshire | |
| Nitrazepam | Insomnia | Double Red | n/a | Hertfordshire and West Essex ICB |
| Omega 3 fatty acid | Primary or secondary prevention of CVD, sleep problems, multiple sclerosis (MS), familial hypercholesterolemia | Double Red | Prescribing guideline | Hertfordshire and West Essex ICB |
| Omega-3 Fatty Acids Patient Information Leaflet | Primary or secondary prevention of CVD, sleep problems, multiple sclerosis (MS), familial hypercholesterolemia | n/a | Patient information | Hertfordshire and West Essex ICB |
| Open MRI | n/a | Clinical policy | Hertfordshire and West Essex ICB | |
| Open Mri Prior Approval Form | n/a | Prior approval form | Hertfordshire and West Essex ICB | |
| Opicapone | Parkinson's disease | Amber initiation | n/a | Hertfordshire and West Essex ICB |
| Opioid | Pain - persistent self care | n/a | Prescribing guideline | Hertfordshire and West Essex ICB |
| Opioid | Pain - plan agreement | n/a | Patient information | Hertfordshire and West Essex ICB |
| Opioid | Pain - review letter | n/a | Primary Care prescribing resource | Hertfordshire and West Essex ICB |
| Opioid Aware Campaign | n/a | Primary Care prescribing resource | Hertfordshire and West Essex ICB | |
| Opioid Deprescribing | Pain - long-term prescribing for non-cancer, chronic pain in adults | n/a | Position statement | Hertfordshire and West Essex ICB |
| Opioid fact sheet | Pain | Green | Patient information | Hertfordshire and West Essex ICB |
| Opioid reduction | Opioid reduction tool | n/a | Primary Care prescribing resource | Hertfordshire and West Essex ICB |
| Orphenadrine | Parkinson's disease | Amber initiation | n/a | Hertfordshire and West Essex ICB |
| Oxcarbazepine | Epilepsy | Amber initiation | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Oxycodone and naloxone | Pain | Double Red | Prescribing guideline | Hertfordshire and West Essex ICB |
| Oxycodone and Naloxone combination products Patient Information Leaflet | Pain | n/a | Patient information | Hertfordshire and West Essex ICB |
| Paracetamol and tramadol | Pain | Double Red | Prescribing guideline | Hertfordshire and West Essex ICB |
| Paracetamol and Tramadol combination products Patient Information Leaflet | Pain | n/a | Patient information | Hertfordshire and West Essex ICB |
| Peginterferon and ropeginterferon | Hepatitis and Multiple sclerosis (NHSE) | Red | Decision document | Hertfordshire and West Essex ICB |
| Pentosan polysulfate sodium | Bladder pain syndrome | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Phenobarbital | Epilepsy | Amber initiation | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Phenytoin | Epilepsy | Green | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Pitolisant | Excessive daytime sleepiness caused by obstructive sleep apnoea | Double Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Pramipexole | Parkinson's disease | Amber initiation | n/a | Hertfordshire and West Essex ICB |
| Prednisolone | All indications - soluble tablet | n/a | Patient information | Hertfordshire and West Essex ICB |
| Prednisolone enteric coated | All indications | Double Red | n/a | Hertfordshire and West Essex ICB |
| Primidone | Epilepsy | Amber initiation | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Procyclidine | Parkinson's disease | Green | n/a | Hertfordshire and West Essex ICB |
| Promethazine | All indications | n/a | Position statement | Hertfordshire and West Essex ICB |
| Rapid Onset Isolated Visual Loss (No other neurological symptoms or signs) | n/a | Clinical pathways | Hertfordshire and West Essex ICB | |
| Rasagiline | Parkinson's disease | Amber initiation | n/a | Hertfordshire and West Essex ICB |
| Riluzole | Amyotrophic Lateral Sclerosis (ALS) form of Motor Neurone Disease (MND) | Amber protocol | Shared care protocol | Hertfordshire and West Essex ICB |
| Rimegepant | Migraine - acute treatment | Green | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Rimegepant | Migraine- episodic - prevention | Amber initiation | Prescribing pathway | Hertfordshire and West Essex ICB |
| Rimegepant | Migraine- episodic - prevention | Amber initiation | Prescribing support document | Hertfordshire and West Essex ICB |
| Rivastigmine | Alzheimer's disease dementia | Amber initiation | Prescribing support document | East and North Hertfordshire, South and West Hertfordshire |
| Rivastigmine | Alzheimer's disease dementia | Amber protocol | Shared care protocol | West Essex |
| Ropinirole | Parkinson's disease | Amber initiation | n/a | Hertfordshire and West Essex ICB |
| Rotigotine | Parkinson's disease | Amber initiation | n/a | Hertfordshire and West Essex ICB |
| Sativex® and other licensed cannabis -based medicinal products | Red | Decision document | Hertfordshire and West Essex ICB | |
| Selective serotonin reuptake inhibitors (SSRIs) | Narcolepsy (tertiary centre only) some have agreed amber protocol | Amber initiation | n/a | Hertfordshire and West Essex ICB |
| Selegiline | Parkinson's disease | Amber initiation | n/a | Hertfordshire and West Essex ICB |
| Seroquel 100mg tablets to generic-switch-letter | Schizophrenia/Bipolar | n/a | Patient information | Hertfordshire and West Essex ICB |
| Shared care | Attention deficit hyperactivity disorder (ADHD) by Private Provider | Amber protocol | Primary Care prescribing resource | Hertfordshire and West Essex ICB |
| Siponimod | Multiple sclerosis (NHSE) | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Sodium oxybate | Narcolepsy with cataplexy (tertiary centre only) | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
| Sodium valproate | All indications | Amber initiation | Primary Care prescribing resource | Hertfordshire and West Essex ICB |
| Solriamfetol | Excessive daytime sleepiness caused by narcolepsy (tertiary centre only) | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Solriamfetol apnoea | Excessive daytime sleepiness caused by obstructive sleep apnoea | Double Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Spinal Cord Stimulation | n/a | Clinical policy | Hertfordshire and West Essex ICB | |
| Stroke | n/a | Clinical pathways | Hertfordshire and West Essex ICB | |
| Tapentadol IR | Pain - acute moderate to severe | Double Red | n/a | Hertfordshire and West Essex ICB |
| Teriflunomide | Relapsing–remitting multiple sclerosis (NHSE) | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| TIA (Transient Ischemic Attack) | n/a | Clinical pathways | East and North Hertfordshire | |
| Topiramate | Epilepsy | Amber initiation | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Transcranial Magnetic Stimulation (TMS and rTMS) | n/a | Clinical policy | Hertfordshire and West Essex ICB | |
| Trazodone oral solution to capsules switch Patient letter | Licensed Indications | n/a | Primary Care prescribing resource | Hertfordshire and West Essex ICB |
| Tremor in Primary Care |Initial Assessment | n/a | Clinical pathways | Hertfordshire and West Essex ICB | |
| Trihexyphenidyl (Benzhexol) | Parkinson's disease | Green | n/a | Hertfordshire and West Essex ICB |
| Trimipramine - stopping and switching guidance | Depression | Double Red | Primary Care prescribing resource | Hertfordshire and West Essex ICB |
| Varenicline | Smoking cessation | Green | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Venlafaxine | Narcolepsy (tertiary centre only) some have agreed amber protocol | Amber initiation | n/a | Hertfordshire and West Essex ICB |
| Venlafaxine oral solution to Tablets Patient Letter | Licensed Indications | n/a | Primary Care prescribing resource | Hertfordshire and West Essex ICB |
| Vigabatrin | Epilepsy | Amber initiation | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Zolmitriptan tablets to orodispersible tablets switch patient letter | Migraine | Green | Patient information | Hertfordshire and West Essex ICB |
| Zonegran caps to generic -switch-letter | Epilepsy | n/a | Patient information | Hertfordshire and West Essex ICB |
| Zonisamide capsules | Epilepsy | Amber initiation | Decision document | Hertfordshire and West Essex ICB |
| Zonisamide oral liquids | Epilepsy | Double Red | Decision document | Hertfordshire and West Essex ICB |